Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

Group 1: Earnings Performance - Cue Biopharma reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.16, and improved from a loss of $0.28 per share a year ago, representing an earnings surprise of 18.75% [1] - The company has surpassed consensus EPS estimates in all four of the last quarters [2] - The revenue for the quarter ended December 2024 was $1.58 million, missing the Zacks Consensus Estimate by 5.40%, and down from $1.82 million year-over-year [2] Group 2: Stock Performance and Outlook - Cue Biopharma shares have declined approximately 15.6% since the beginning of the year, compared to a decline of 5.1% for the S&P 500 [3] - The company's earnings outlook is mixed, with the current consensus EPS estimate for the coming quarter at -$0.15 on $2 million in revenues, and -$0.55 on $13.49 million in revenues for the current fiscal year [7] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which Cue Biopharma belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]